港股異動 | 復星醫藥(2196.HK)漲4.75% 子公司開展SVN53-67/M57-KLH肽疫苗II期臨牀試驗獲批
格隆匯3月21日丨復星醫藥(2196.HK)漲4.75%,報35.3港元,總市值904億港元。該公司3月18日盤後發佈公吿,子公司上海復星醫藥產業發展有限公司(以下簡稱“復星醫藥產業”)收到國家藥品監督管理局關於同意其獲許可引進的SVN53-67/M57-KLH肽疫苗(即SurVaxM,以下簡稱“該新藥”)聯合替莫唑胺輔助治療初診的膠質母細胞瘤開展臨牀試驗的批准。復星醫藥產業擬於條件具備後於中國境內(不包括港澳台,下同)開展該新藥的II期臨牀試驗。該新藥是一種新型腫瘤免疫治療產品。2019年11月,復星醫藥產業就該新藥獲得MimiVax,LLC在區域內(即中國大陸、香港及澳門特別行政區)及領域內(即膠質母細胞瘤以及其他腫瘤和非腫瘤適應症的治療和預防)的獨家臨牀開發和商業化許可。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.